2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment optionsUsing real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar.
Li Y, Yang S, Chiang A, Gross C, Wang S. Using real world practice patterns to identify clinical equipoise in cancer treatment: Advanced non-small cell lung cancer as an exemplar. JCO Oncology Practice 2023, 19: 539-539. DOI: 10.1200/op.2023.19.11_suppl.539.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerPD-L1 1First-line therapyCell lung cancerTreatment patternsECOG 2PD-L1Clinical equipoiseLung cancerHHI scoresEastern Cooperative Oncology Group performance scoreFirst-line treatment regimensReal-world practice patternsALK/EGFRActionable gene alterationsStandard of careConfidence intervalsGroup performance scoreComparative effectiveness researchECOG statusOverall cohortPerformance statusECOG scoreTreatment regimensAssociation Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gain
2021
Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.
Jairam V, Pasha S, Soulos P, Goldberg S, Yu J, Decker R, Gross C, Park H. Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer. Journal Of Clinical Oncology 2021, 39: e20550-e20550. DOI: 10.1200/jco.2021.39.15_suppl.e20550.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerTumor characteristicsLung cancerFDA approvalConsolidative durvalumabPatient characteristicsUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerAdvanced non-small cell lung cancerFirst-line platinum-doublet chemotherapyStudy periodFlatiron Health databasePlatinum-doublet chemotherapyGuideline-concordant carePD-L1 statusMultivariable logistic regressionCochran-Armitage testDe-identified databaseChi-square testDefinitive chemoradiationDoublet chemotherapyEligible patientsPACIFIC trialSurgery details
2020
The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.Peer-Reviewed Original ResearchMetastatic breast cancerMetastatic colorectal cancerAdvanced non-small cell lung cancerNational coverage decisionNGS testingUtilization trendsNext-generation sequencingNGS testsNon-small cell lung cancerCell lung cancerInterrupted time series analysisDe-identified databaseDiagnosis dateAdvanced melanomaPrimary cancerRetrospective studyColorectal cancerLung cancerInsurance typeCancer clinicMetastatic cancerBreast cancerUse of NGSTesting ratesCancer
2019
1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Cohen A, Neri B, Adamson B, Scanlon C, Gross C, Meropol N, Miksad R. 1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC). Annals Of Oncology 2019, 30: v642. DOI: 10.1093/annonc/mdz260.080.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerFlatiron HealthOverall survivalBiomarker statusOlder ptsNon-small cell lung cancerAge groupsFred Hutchinson Cancer Research CenterMedian overall survivalNon-squamous histologyCell lung cancerProportional hazards regressionReal-world populationCancer Research CenterAge-related outcomesPDL1 statusLonger OSSimilar OSStage IIIBBaseline characteristicsMetastatic NSCLCPrognostic factorsSmoking statusHazards regressionLung cancerReal-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerPD-L1 expression testingFirst-line therapyNon-small cell lung cancerPD-L1 expressionPD-L1 testingCell lung cancerLung cancerFlatiron Health electronic health record-derived databaseElectronic health record-derived databaseCell death ligand 1 (PD-L1) expressionFDA approvalDeath ligand 1 (PD-L1) expressionReal-world practice patternsFirst-line treatmentLigand 1 expressionProportion of patientsMonths of diagnosisReal-world careMultivariable logistic regressionCommunity oncology practicesCompanion diagnostic testingExpression testingIdentifiable driver mutationsLine treatment
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancerAdoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.Peer-Reviewed Original ResearchElectronic health record databaseReal-world practiceCheckpoint inhibitorsAdvanced non-small cell lung cancerFDA approvalNon-small cell lung cancerDeath-1 checkpoint inhibitorsMetastatic renal cell carcinomaAdoption of immunotherapyGeneralizability of trialsCell lung cancerRenal cell carcinomaDrug Administration approvalHealth record databaseChi-square testStudy drugOlder patientsSystemic therapyAdvanced melanomaMedian ageTherapy linesCell carcinomaLung cancerAdministration approvalClinical trialsDisparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.
Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerNGS testingLung cancerBiomarker testingOncology practiceNext-generation sequencingNon-squamous non-small cell lung cancerPopulation-based community cohortReal-world clinical practiceMulti-gene panel testingInsurance-related disparitiesAdvanced lung cancerFirst-line treatmentHistory of smokingRetrospective observational studyElectronic health record dataWorld clinical practiceClustering of patientsHealth record dataYounger patientsMedian agePatient characteristicsWhite patients